Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
批准号:
8437094
负责人:
PETER E MORRIS
金额:
$50.8万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-08 至 2015-03-31
关键词:
Activities of Daily LivingAcuteAcute respiratory failureAffectAgingBasic ScienceBiological MarkersBudgetsCaringClinicalClinical Trials DesignConsensusContractureCritical CareCritical IllnessDataDiscipline of NursingDyspneaEnrollmentEnvironmentExerciseExercise PhysiologyExhibitsFundingGrantHealthHeart failureHospital CostsHospitalizationHospitalsInflammationIntensive Care UnitsJointsLength of StayMeasuresMechanical ventilationMedicineMental DepressionMuscle WeaknessOutcomePassive Range of Motion functionPatientsPerformancePhysical therapyProtocols documentationPublishingQuality of lifeRecoveryRegimenRehabilitation therapyResearchResearch PersonnelResistanceSafetySocietiesTestingTimeTrainingWorkagedarmcostcritical care nursingexperiencefollow-upfunctional outcomesfunctional statushealth economicshealth related quality of lifeimprovedinnovationinterestmultidisciplinarynovelrandomized trialrespiratorystrength trainingtreatment as usualtrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Acute Respiratory Failure (ARF) requiring mechanical ventilation affects 1.1 million of the 4.4 million people admitted to US Intensive Care Units (ICU) every year. Patients with ARF experience deconditioning, muscle weakness, joint contractures, dyspnea, depression, and reduced health-related quality of life, all of which may contribute to prolonged hospitalization and increased costs. Patients with ARF average 15 hospital days with median costs of $30,000. Critical care rehabilitative therapy for patients with ARF is not uniform in its content, timing or the acceptance of its safety. Our published data indicate that Standardized Rehabilitation Therapy, initiated in the ICU, is feasible and safe. The pilot showed a trend in reduced hospital stay, but functional outcomes were not determined. Therefore, for the acceptance of Standardized Rehabilitation Therapy in US hospitals to advance, this study will demonstrate that Standardized Rehabilitation Therapy for patients with ARF reduces hospital stay through immediate improvement in functional capacity and functional performance. Mechanistically, it is understood that patients with ARF exhibit acute inflammation and since rehabilitation increases functional outcomes and lowers biomarkers of inflammation in heart failure and the frail aging, we will determine whether the anticipated improvements in ARF patient outcomes are associated with a reduction in biomarkers of inflammation. The proposed study will test the following hypotheses: 1) Standardized Rehabilitation Therapy will shorten hospital stay in patients with ARF; 2) Standardized Rehabilitation Therapy will improve objective functional measures and quality of life at 6 months post-enrollment; 3) Standardized Rehabilitation Therapy will reduce biomarkers of inflammation; 4) Standardized Rehabilitation Therapy will decrease hospital costs. We will conduct a two-arm, randomized trial in 326 patients with ARF to compare Standardized Rehabilitation Therapy, initiated in the ICU and administered throughout the hospitalization, vs. Usual Care (control). Standardized Rehabilitation Therapy will consist of: passive range of motion, physical therapy and progressive resistance exercise (strength training). Our unique environment provides a hospital-funded, experienced Mobility Team (7days/week) consisting of a critical care nurse, physical therapist and nursing assistant to administer this protocol. The proposed study is a natural extension of our prior work, is multidisciplinary (Exercise Physiology, Physical Therapy, Nursing, Medicine, Basic Science, Health Economics), is supported by extensive preliminary studies, is innovative, and is responsive to recent society consensus statements.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Wake Forest Clinical Center for the NHLBI PETAL Network
-
批准号:8707119
-
项目类别:
-
资助金额:$13.68万
-
财政年份:2014
-
负责人:PETER E MORRIS
-
依托单位:
PATIENT OUTCOMES 6 AND 12 MONTHS AFTER ALTA, EDEN AND OMEGA ARDS NETWORK TRIAL
-
批准号:8167040
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2010
-
负责人:PETER E MORRIS
-
依托单位:
STANDARDIZED REHABILITATION THERAPY FOR ICU PATIENTS WITH ACUTE (TARGET)
-
批准号:8167049
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2010
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:7636485
-
项目类别:
-
资助金额:$56.0万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:7837757
-
项目类别:
-
资助金额:$49.96万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:8247041
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
PATIENT OUTCOMES 6 AND 12 MONTHS AFTER ALTA, EDEN AND OMEGA ARDS NETWORK TRIAL
-
批准号:7951415
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:8039976
-
项目类别:
-
资助金额:$49.4万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
GENETIC PREDISPOSITION TO TRANSIENT ADRENAL DYSFUNCTION IN SEVERE SEPSIS
-
批准号:7376682
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2006
-
负责人:PETER E MORRIS
-
依托单位:
GENETIC PREDISPOSITION TO TRANSIENT ADRENAL DYSFUNCTION IN SEVERE SEPSIS
-
批准号:7203846
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2005
-
负责人:PETER E MORRIS
-
依托单位:
ASSESS FACTORS ASSOCIATED WITH LUNG FUNCTION RECOVERY FOLLOWING THE ARDS
-
批准号:7203811
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2005
-
负责人:PETER E MORRIS
-
依托单位:
Assess Factors Associated with Lung Function Recovery Following the ARDS
-
批准号:7045680
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2004
-
负责人:PETER E MORRIS
-
依托单位:
Genetic Predisposition to Transient Adrenal Dysfunction in Severe Sepsis
-
批准号:7045729
-
项目类别:
-
资助金额:$8.46万
-
财政年份:2004
-
负责人:PETER E MORRIS
-
依托单位:
海外基金